OHR Pharmaceutical, Inc. (NASDAQ:OHRP) is headquartered in New York, New York, USA, with 3 full-time employees. It is a clinical-stage pharmaceutical company that develops new treatments for eye diseases.
OHR Pharmaceutical (OHRP):
OHR Pharmaceutical has completed two clinical trials using a 0.2% squalamine lactate ophthalmic solution for the treatment of wet age-related macular degeneration.
In addition, OHR Pharmaceuticals also has a slow-release micro-manufactured microparticle ophthalmic drug delivery platform technology.
The company intends to merge with NeuBase Therapeutics, Inc., focusing on advancing NeuBase’s peptide-nucleic acid antisense oligonucleotide technology platform for the development of therapeutic methods to solve serious and currently incurable diseases caused by genetic mutations.